MedPAC considers 3 different options for regulating the price of Part B drugs

This Weekly’s Hot Topics

  • Centene takes over Medi-Cal Rx contractor California News
  • MedPAC considers 3 different options for regulating the price of Part B drugs Medicare News/CMS News
  • House & Senate introduce like bills affecting physician prescribing National News

The company that was awarded the state’s Medi-Cal prescription drug contract was taken over by insurer Centene, which has been accused of overbilling nine other state Medicaid programs. To read more click here and go to California News.

Members, and staff, of the Medicare Payment Advisory Commission (MedPAC) considered three different options for regulating the price of Part B drugs, which are administered by physicians in their offices. 1) For new “first-in-class” drug, 2) For drugs that already have therapeutic alternatives, and 3) To address concerns about the ASP-plus-6% reimbursement formula. To read more click here and go to Medicare News/CMS News.

It would be illegal to compel clinicians to write “dispense as written” on a prescription when a biosimilar or a generic is available per the Generic Substitution Non-Interference Act, introduced in the House and Senate last Thursday. To read more click here and go to National News.

To read the full edition of the California Oncology Weekly Newsletter, click on the date below.

April 12, 2022



No comments have been posted yet.